Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

AIDS

Volumn 25, Issue 12, 2011, Pages 1497-1504

  Worm, Signe W ^a   Kamara, David A ^b   Reiss, Peter ^c   Kirk, Ole ^a   El Sadr, Wafaa ^d   Fux, Christoph ^e   Fontas, Eric ^f   Phillips, Andrew ^b,c   D'Arminio Monforte, Antonella ^g   De Wit, Stephane ^h   Petoumenos, Kathy ⁱ   Friis Møller, Nina ^a   Mercie, Patrick ^j   Lundgren, Jens D ^a   Sabin, Caroline ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c STICHTING HIV MONITORING   (Netherlands)

^d Howard Hughes Medical Institute   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g UNIVERSITY OF MILAN   (Italy)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

epidemiology; HIV; myocardial infarction; risk factors; triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; FEMALE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 79960564501     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834917c6     Document Type: Article

References (26)

1. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIVinfected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
2. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
3. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008; 34 (6 Pt 2):649-657.
4. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51:679-689.
5. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
6. Phillips AN, Carr A, Neuhaus J, Visnegarwalda F, Prineas R, Burman WJ, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187. (Pubitemid 351535369)
7. Stein JH, Merwood MA, Bellehumeur JB, McBride PE, Wiebe DA, Sosman JM. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol 2005; 25:399-405. (Pubitemid 40189164)
8. Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb 2003; 10:132-139.
9. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421-425. (Pubitemid 41723310)
10. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:64-74.
11. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074. (Pubitemid 38373099)
12. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
13. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-330.
14. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308. (Pubitemid 47080484)
15. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316. (Pubitemid 47080485)
16. Di Angelantonio AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
17. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation 2007; 115:450-458. (Pubitemid 46184196)
18. Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007; 147:377-385. (Pubitemid 351664538)
19. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372:224-233. (Pubitemid 351978112)
20. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Nonfasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993; 307:1318-1322. (Pubitemid 23337748)
21. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163:1077-1083. (Pubitemid 36548936)
22. Egger M, Smith GD, Pfluger D, Altpeter E, Elwood PC. Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis 1999; 143:275-284. (Pubitemid 29166908)
23. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21:757-767. (Pubitemid 41434180)
24. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47:459-466. (Pubitemid 351366958)
25. European AIDS Clinical Society. EACS Guidelines. Version 5-4, 2009. http://www.europeanaidsclinicalsociety.org/guidelines. asp.
26. Frost C, White IR. The effect of measurement error in risk factors that change over time in cohort studies: do simple methods overcorrect for 'regression dilution'? Int J Epidemiol 2005; 34:1359-1368. (Pubitemid 41819545)